Sign In
Buy RCKT
$2.92
+0.0300 (+1.04%)
At Close: Jun 03, 2026
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Comp
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
06:25pm, Wednesday, 28'th May 2025
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such in
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
03:35pm, Wednesday, 28'th May 2025
Rocket Pharmaceuticals Inc RCKT on Tuesday announced an update related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with th
Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Connect
03:15pm, Wednesday, 28'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Comp
RCKT Stock Tanks on Patient Death in Danon Disease Study
12:11pm, Wednesday, 28'th May 2025
Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts a clinical hold on the study.
These Analysts Slash Their Forecasts On Rocket Pharmaceuticals
08:22am, Wednesday, 28'th May 2025
Rocket Pharmaceuticals Inc RCKT announced an update Tuesday related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the cl
Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold
11:07am, Tuesday, 27'th May 2025
Rocket Pharmaceuticals Inc RCKT announced an update Tuesday related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the c
Rocket Pharmaceuticals shares plunge after FDA halts key gene therapy trial following patient death
10:37am, Tuesday, 27'th May 2025
Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) sank nearly 60% on Tuesday morning after the company disclosed that the US Food and Drug Administration had placed a clinical hold on its pivotal Phase I
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease
07:00am, Tuesday, 27'th May 2025
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseas
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
11:45am, Friday, 09'th May 2025
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
Rocket Pharma Out Of Orbit, But Ready For Relaunch
11:16am, Thursday, 10'th Apr 2025
Rocket Pharmaceuticals' gene therapies offer long-term effects for cardiovascular and hematology diseases, addressing severe unmet needs like Danon Disease, which currently requires heart transplants.
Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
07:00am, Thursday, 03'rd Apr 2025
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
02:30pm, Friday, 28'th Feb 2025
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.
